Acipimox


Thông tin thuốc gốc
Chỉ định và Liều dùng
Oral
Fredrickson type IIb hyperlipoproteinaemia, Fredrickson type IV hyperlipoproteinaemia
Adult: As an alternative or adjunct in patients who have not responded adequately to other treatments (e.g. statins, fibrates): Usual dose: 250 mg bid or tid. Dose is individualised based on the patient's plasma triglyceride and cholesterol levels. Dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).
Suy thận
Dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).

CrCl (mL/min) Dosage
<30 Contraindicated.
30-60 250 mg once daily or bid.
Cách dùng
Should be taken with food. Take w/ or after meals.
Chống chỉ định
Active peptic ulcer. Severe renal impairment (CrCl <30 mL/min). Pregnancy and lactation. Contraindications may vary among individual products (refer to specific product labelling for detailed information).
Thận trọng
Patient with acute haemorrhage; heart failure. Management with dietary changes and other non-pharmacological treatments (e.g. exercise, weight reduction, smoking or alcohol cessation) should be attempted prior to initiating treatment. Hepatic and mild to moderate renal impairment.
Tác dụng không mong muốn
Significant: Pruritus, flushing, erythema, rash.
Eye disorders: Eye irritation, dry eyes.
Gastrointestinal disorders: Dyspepsia, upper abdominal pain, nausea, diarrhoea.
General disorders and administration site conditions: Asthenia, malaise, feeling hot.
Immune system disorders: Anaphylactoid reaction.
Musculoskeletal and connective tissue disorders: Myalgia, arthralgia, myositis.
Nervous system disorders: Headache.
Respiratory, thoracic and mediastinal disorders: Bronchospasm.
Skin and subcutaneous tissue disorders: Urticaria, angioedema.
Vascular disorders: Vasodilation.
Chỉ số theo dõi
Monitor lipid profile, liver and kidney function at baseline and periodically during therapy.
Tương tác
May enhance the myopathic (rhabdomyolysis) effect of statins and fibrates.
Tác dụng
Description: Acipimox lowers blood cholesterol by inhibiting the release of fatty acids from adipose tissue and reducing serum levels of VLDL and LDL with a subsequent overall lowering of triglyceride and cholesterol levels. Additionally, it increases HDL concentrations during treatment.
Pharmacokinetics:
Absorption: Rapidly and completely absorbed from the gastrointestinal tract. Time to peak plasma concentration: Approx 2 hours.
Metabolism: Not significantly metabolised.
Excretion: Via urine (mainly unchanged). Elimination half-life: Approx 2 hours.
Đặc tính

Chemical Structure Image
Acipimox

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 5310993, Acipimox. https://pubchem.ncbi.nlm.nih.gov/compound/Acipimox. Accessed May 26, 2022.

Bảo quản
Store below 30°C. Protect from moisture.
Phân loại MIMS
Thuốc trị rối loạn lipid máu
Phân loại ATC
C10AD06 - acipimox ; Belongs to the class of nicotinic acid and derivatives. Used in the treatment of hyperlipidemia.
Tài liệu tham khảo
Anon. Acipimox. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 13/01/2022.

Buckingham R (ed). Acipimox. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 13/01/2022.

Joint Formulary Committee. Acipimox. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 13/01/2022.

Olbetam 250 mg Capsules (Pfizer Limited). MHRA. https://products.mhra.gov.uk. Accessed 13/01/2022.

Pfizer New Zealand Limited. Olbetam 250 mg Capsule data sheet 3rd May 2019. Medsafe. http://www.medsafe.govt.nz. Accessed 13/01/2022.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Acipimox từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in